Watch
Sulzer to Acquire Simcro, a Global Provider of Animal Health Pharmaceutical Delivery Devices
Winterthur, (PresseBox) -
Sulzer signed a binding agreement to acquire Simcro. Simcro is the market leader for pharmaceutical delivery devices such as injectors and applicators for livestock and companion animals. The acquisition adds animal health care as a new, attractive market segment to Sulzer’s Applicator Systems division. The enterprise value is NZD 132 million (CHF 90 million).
Simcro, headquartered in Hamilton, New Zealand, is expected to achieve revenues of CHF 35 million and an EBITDA margin of 27% in 2017. The company generates 30% of its revenues in Europe, Middle East, and Africa; 40% in the Americas; and 30% in Asia-Pacific. It employs 230 people. Simcro operates two manufacturing locations — one in New Zealand and one in Australia — and focuses on B2B customers. Its delivery systems inject or orally apply pharmaceuticals to livestock and companion animals. Simcro’s proprietary intellectual property includes enhancing treatment efficacy, user safety, operational convenience, and animal welfare.
Simcro will become part of Sulzer’s Applicator Systems division, and its current management team will stay with the company. Following the acquisitions of PC Cox and Geka in 2016, Simcro is Sulzer’s third acquisition to strengthen its Applicator Systems division.
The transaction is expected to close in the third quarter of 2017 subject to foreign investment approval in New Zealand.
Amaury de Menthière, Division President of Applicator Systems, said, “We are very excited to welcome Simcro’s team of experienced animal health experts to Sulzer and to become a leading supplier of pharmaceutical delivery systems in the global animal health care market with a comprehensive and innovative range of injectors and applicators. We are convinced that our global reach in Applicator Systems can accelerate the development of Simcro.”
This document may contain forward-looking statements including, but not limited to, projections of financial developments, market activity, or future performance of products and solutions containing risks and uncertainties. These forward-looking statements are subject to change based on known or unknown risks and various other factors that could cause actual results or performance to differ materially from the statements made herein.
Simcro, headquartered in Hamilton, New Zealand, is expected to achieve revenues of CHF 35 million and an EBITDA margin of 27% in 2017. The company generates 30% of its revenues in Europe, Middle East, and Africa; 40% in the Americas; and 30% in Asia-Pacific. It employs 230 people. Simcro operates two manufacturing locations — one in New Zealand and one in Australia — and focuses on B2B customers. Its delivery systems inject or orally apply pharmaceuticals to livestock and companion animals. Simcro’s proprietary intellectual property includes enhancing treatment efficacy, user safety, operational convenience, and animal welfare.
Simcro will become part of Sulzer’s Applicator Systems division, and its current management team will stay with the company. Following the acquisitions of PC Cox and Geka in 2016, Simcro is Sulzer’s third acquisition to strengthen its Applicator Systems division.
The transaction is expected to close in the third quarter of 2017 subject to foreign investment approval in New Zealand.
Amaury de Menthière, Division President of Applicator Systems, said, “We are very excited to welcome Simcro’s team of experienced animal health experts to Sulzer and to become a leading supplier of pharmaceutical delivery systems in the global animal health care market with a comprehensive and innovative range of injectors and applicators. We are convinced that our global reach in Applicator Systems can accelerate the development of Simcro.”
This document may contain forward-looking statements including, but not limited to, projections of financial developments, market activity, or future performance of products and solutions containing risks and uncertainties. These forward-looking statements are subject to change based on known or unknown risks and various other factors that could cause actual results or performance to differ materially from the statements made herein.
